寻求ERBB2阳性转移性乳腺癌的定制化治愈:综述
本综述探讨ERBB2阳性转移性乳腺癌中部分患者经化疗联合ERBB2阻断可获得持久缓解、近似治愈的现象。文章总结识别长期缓解者的临床病理特征,并讨论曲妥珠单抗德鲁替康、图卡替尼、马格妥昔单抗等新药用于前线治疗升级的潜在价值。
要点
- 长期缓解者倾向为初诊即转移、疾病负荷较低、对系统治疗反应深。
- 病理特征为ERBB2高表达、无有害基因组异常及抗肿瘤免疫激活。
- 该人群可能从曲妥珠单抗德鲁替康、图卡替尼或马格妥昔单抗的前线升级治疗中获益。
核心结论
- 谨慎应用新型诊断与治疗工具可能扩大ERBB2阳性转移性乳腺癌长期缓解人群。
- 试验正在筹备以证实该范式,并有望引领乳腺癌精准治疗新时代。
研究设计与样本
- 综述,总结ERBB2阳性转移性乳腺癌治愈相关临床与病理特征及治疗进展。
主要发现
- 部分ERBB2阳性转移性乳腺癌患者对化疗联合ERBB2阻断获得持久缓解,近似治愈。
- 长期缓解者倾向为初诊即转移、疾病负荷较低、对系统治疗反应深。
- 与长期缓解相关的病理特征为ERBB2高表达、无有害基因组异常及抗肿瘤免疫激活。
- 该人群可能从曲妥珠单抗德鲁替康、图卡替尼或马格妥昔单抗等新药的前线治疗升级中获益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Metastatic breast cancer (MBC) has traditionally been considered incurable. Accordingly, current treatment algorithms are aimed at maintaining quality of life and improving overall survival, rather than at complete eradication of the disease. Attempts to achieve cure with high-dose chemotherapy were conducted in the 1990s, with no observed long-term benefit compared with conventional chemotherapy. Nonetheless, Erb-B2 receptor tyrosine kinase 2 (ERBB2, formerly HER2)-targeted biologic treatments, developed in the past 2 decades, are currently challenging this paradigm. Indeed, a fraction of patients with ERBB2-positive MBC achieve long-lasting responses to chemotherapy and ERBB2-blockade, resembling a cure. In this setting, the challenge of identifying the optimal curable population has emerged, including identifying populations in whom treatment escalation strategies may be beneficial, while avoiding overtreatment in patients with incurable disease. OBSERVATIONS: A number of clinical and pathologic features allow physicians to identify patients with ERBB2-positive MBC who are more likely to experience a long-lasting response to chemotherapy and ERBB2-blockade. Long-term responders tend to be de novo metastatic, have a reduced disease burden, and tend to show deep responses to systemic treatment. In pathologic terms, features associated with long-term response are high ERBB2 expression, lack of detrimental genomic aberrations, and antitumor immune activation. This population of patients may potentially derive benefit from a tailored escalation of frontline treatment with novel anti-ERBB2 drugs, such as trastuzumab deruxtecan, tucatinib, or margetuximab. Additional recent therapeutic and diagnostic advancements could further aid in the path toward a cure for ERBB2-positive MBC. CONCLUSIONS AND RELEVANCE: Careful implementation of novel diagnostic and treatment tools could potentially expand the population of patients with ERBB2-positive MBC experiencing long-lasting disease response. Trials are in preparation to confirm this paradigm, and hopefully lead to a new era of precision therapy for breast cancer.
引用
- Tarantino P, Curigliano G, Parsons HA, et al. Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review. JAMA Oncol. 2022. PMID: 35024766. doi:10.1001/jamaoncol.2021.6597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。